Hyperfine characterization of tin-doped indium sesquioxide

The hyperfine interactions at In and Sn sites of In2O3∶Sn (ITO) were measured through time-differential perturbed angular correlations and Mossbauer spectroscopy, respectively. Polycrystalline samples prepared by co-precipitation with nominal 0.025, 1 and 5 at.% Sn were studied. They all showed the cubic bixbyite structure characteristic of In2O3 after annealings at 200 °C. The quadrupole interaction at In sites appears nearly independent of Sn concentration being the main result of the presence of Sn in the lattice, the gradual disappearence of the dynamic perturbation caused by after-effects. The Mossbauer data demonstrate that Sn ions are in a 4+ state with ΔQ=0.606 mm/s andδ=0.226 mm/s relative to SnO3Ca at room temperature.Facultad de Ciencias Exacta

Jardins per a la salut

Facultat de Farmàcia, Universitat de Barcelona. Ensenyament: Grau de Farmàcia. Assignatura: Botànica farmacèutica. Curs: 2014-2015. Coordinadors: Joan Simon, Cèsar Blanché i Maria Bosch.Els materials que aquí es presenten són el recull de les fitxes botàniques de 128 espècies presents en el Jardí Ferran Soldevila de l’Edifici Històric de la UB. Els treballs han estat realitzats manera individual per part dels estudiants dels grups M-3 i T-1 de l’assignatura Botànica Farmacèutica durant els mesos de febrer a maig del curs 2014-15 com a resultat final del Projecte d’Innovació Docent «Jardins per a la salut: aprenentatge servei a Botànica farmacèutica» (codi 2014PID-UB/054). Tots els treballs s’han dut a terme a través de la plataforma de GoogleDocs i han estat tutoritzats pels professors de l’assignatura. L’objectiu principal de l’activitat ha estat fomentar l’aprenentatge autònom i col·laboratiu en Botànica farmacèutica. També s’ha pretès motivar els estudiants a través del retorn de part del seu esforç a la societat a través d’una experiència d’Aprenentatge-Servei, deixant disponible finalment el treball dels estudiants per a poder ser consultable a través d’una Web pública amb la possibilitat de poder-ho fer in-situ en el propi jardí mitjançant codis QR amb un smartphone

The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

Background: Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at ICU admission. Methods: Multicenter, observational, cohort study includes consecutive patients with COVID-19 admitted to 44 Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ventilation for more than three days. We collected demographic and clinical data prior to admission; information about clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes. Results: Of the 2,095 patients with COVID-19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and remained under mechanical ventilation at day three. From days 1 to 3, PaO2/FiO2 increased from 115.6 [80.0-171.2] to 180.0 [135.4-227.9] mmHg and the ventilatory ratio from 1.73 [1.33-2.25] to 1.96 [1.61-2.40]. In-hospital mortality was 38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01-1.07], p = 0.030) and creatinine levels (OR 1.05 [CI 1.01-1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93-1.00], p = 0.037) were independently associated with a higher risk of death. No association between mortality and the PaO2/FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47). Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID-19 receiving mechanical ventilation at ICU admission. No association was found in the PaO2/FiO2 variation

Evaluation of factors leading to poor outcomes for pediatric acute lymphoblastic leukemia in Mexico: a multi-institutional report of 2,116 patients

Background and aimsPediatric acute lymphoblastic leukemia (ALL) survival rates in low- and middle-income countries are lower due to deficiencies in multilevel factors, including access to timely diagnosis, risk-stratified therapy, and comprehensive supportive care. This retrospective study aimed to analyze outcomes for pediatric ALL at 16 centers in Mexico.MethodsPatients <18 years of age with newly diagnosed B- and T-cell ALL treated between January 2011 and December 2019 were included. Clinical and biological characteristics and their association with outcomes were examined.ResultsOverall, 2,116 patients with a median age of 6.3 years were included. B-cell immunophenotype was identified in 1,889 (89.3%) patients. The median white blood cells at diagnosis were 11.2.5 × 103/mm3. CNS-1 status was reported in 1,810 (85.5%), CNS-2 in 67 (3.2%), and CNS-3 in 61 (2.9%). A total of 1,488 patients (70.4%) were classified as high-risk at diagnosis. However, in 52.5% (991/1,889) of patients with B-cell ALL, the reported risk group did not match the calculated risk group allocation based on National Cancer Institute (NCI) criteria. Fluorescence in situ hybridization (FISH) and PCR tests were performed for 407 (19.2%) and 736 (34.8%) patients, respectively. Minimal residual disease (MRD) during induction was performed in 1,158 patients (54.7%). The median follow-up was 3.7 years. During induction, 191 patients died (9.1%), and 45 patients (2.1%) experienced induction failure. A total of 365 deaths (17.3%) occurred, including 174 deaths after remission. Six percent (176) of patients abandoned treatment. The 5-year event-free survival (EFS) was 58.9% ± 1.7% for B-cell ALL and 47.4% ± 5.9% for T-cell ALL, while the 5-year overall survival (OS) was 67.5% ± 1.6% for B-cell ALL and 54.3% ± 0.6% for T-cell ALL. The 5-year cumulative incidence of central nervous system (CNS) relapse was 5.5% ± 0.6%. For the whole cohort, significantly higher outcomes were seen for patients aged 1–10 years, with DNA index >0.9, with hyperdiploid ALL, and without substantial treatment modifications. In multivariable analyses, age and Day 15 MRD continued to have a significant effect on EFS.ConclusionOutcomes in this multi-institutional cohort describe poor outcomes, influenced by incomplete and inconsistent risk stratification, early toxic death, high on-treatment mortality, and high CNS relapse rate. Adopting comprehensive risk-stratification strategies, evidence-informed de-intensification for favorable-risk patients and optimized supportive care could improve outcomes

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

IV Congreso internacional 2019: memorias II

La Red de Dirección Estratégica en la Educación Superior (RED-DEES) celebró hace poco tiempo su 10mo Aniversario de constitución. Por ello, con mucho orgullo este libro permite crear un puente en el tiempo y la emoción para Ias 54 Instituciones de Educación Superior que hoy tienen el honor de ser parte de sus miembros. Hace unos 10 años pocos podrían soñar con que la Red hubiera recorrido el camino que nos ha traído hasta aquí; era una idea inicial, tan solo una semilla, que abriría las puertas a un futuro prometedor; se convirtió en un camino hacia la ilusión, ya que en los primeros años nos movíamos entre el deseo y la incertidumbre. Hoy no dejamos de reconocer que fue una decisión riesgosa, pero estábamos dispuestos a asumirla con muchos esfuerzos entre todos. (Apartes del texto)Contiene: 1. La Planificación Estratégica en la Educación Superior: Monitoreo y Seguimiento a la planificación operativa: Herramienta de apoyo para la toma de decisiones / Isaías Hernández Sánchez, María Catalina Tapia López -- La Planificación y su vinculación con los modelos para la calidad, caso UNAH / Javier Alexis Martínez Moncada -- Resultados de un trabajo planificado en la facultad de medicina de la UNNE- Argentina / Erika Sánchez, Silvia García, Patricia Demuth -- Rediseño estratégico y prospectivo de la arquitectura organizacional: experiencia en la Universidad de Managua. Nicaragua / Fernando Valle Meza, Mario Valle Dávila, Dora María Meza Cornavaca -- Factores que favorecen y dificultan la aplicación de la dirección estratégica en la educación superior / Jorge Juan Domínguez Menéndez -- La evaluación de la práctica de la planificación estratégica en instituciones de educación superior de Cuba. Metodología aplicada y principales resultados / José Luis Almuiñas Rivero, Judith Galarza López -- Modelo para el control de la estrategia institucional en la Universidad de Cienfuegos / Katia Rivero Alonso, Judith Galarza López -- Reconstrucción de la senda que se recorrió en los procesos de planificación y evaluación institucional de comunitaria intercultural / Adrián Puerta Ch., Julia Arguello M. -- 2. Evaluación Institucional y gestión de la calidad en las IES: Hacia la instauración de una cultura de mejora continua: Modelo de evaluación del desempeño en la UNAN -Managua / Isaías Hernández Sánchez, Saira del Rosario Figueroa Aguirre -- Estrategias para mejorar la gestión del proceso de autoevaluación institucional con fines de acreditación en la Universidad San Gregorio de Portoviejo / Ximena Guillén Vivas, José Luis Almuiñas Rivero, Judith Galarza López -- Visita de condiciones iniciales para la acreditación institucional en tiempos de pandemia y sus impactos. Relato de una experiencia. Fundación Universitaria Los Libertadores - Colombia / Patricia Martínez Barrios, Orlando Salinas Gómez, Luz Mercedes Flechas Mendoza -- 3. La formación profesional y la calidad de los procesos universitarios: La formación profesional y la calidad de los procesos universitarios / Observal - Honduras, Celeo Emilio Arias -- Describir la satisfacción estudiantil delos egresados del instituto tecnológico superior de tela, ubicado en la ciudad de tela, Atlantida, Honduras / Gustavo Adolfo Rodríguez, Espinoza Carlos Agurcia, Jairo Núñez -- La cadena valor percibido, satisfacción y lealtad para los egresados de la universidad / Katty Johanna Loor Avila, José Antonio Pedraza Rodríguez, Leonor Pérez Naranjo -- El avance del seguimiento a graduados en la universidad nacional de ingeniería / Melvis Daviel Martínez Cano -- Programa de seguimiento de egresados: estudio preliminar de tres servicios universitarios / Rodrigo Horjales -- La formación de valores éticos en los estudiantes de la carrera de derecho con un enfoque RSU: propuesta de una estrategia / Roger Martínez Isaac, Odette Martínez Pérez, Noemí Delgado Álvarez -- El seguimiento de graduados; oferta y demanda de profesionales veterinarios en el Uruguay / José Passarini, Paola Cabral, Brasiliano Rodríguez, Claudia Borlido -- 4. Vinculación con medio y responsabilidad social universitaria: Responsabilidad social y aprendizaje: ideas preliminares / Odette Martínez Pérez, Roxana Chiquito Chillán, Víctor Gómez Rodríguez -- Transversalización de los Objetivos de Desarrollo Sostenible en la Planeación Institucional de la UNAN-León / Marcos Vinicio Sandino Montes -- La Universidad de Pinar del Río del conocimiento y la innovación en función del desarrollo local sostenible / Maricela González Pérez, Carlos Cesar Torres Paez, Saray Nuñez González -- Educación superior socialmente responsable: propuesta de una metodología para su evaluación e implementación en la educación superior ecuatoriana / Odette Martínez Pérez, Luis Alberto Alzate Peralta, Rudy García Cobas -- 5. La Gestión de la Internacionalización de la educación superior: La gestión del proceso de internacionalización: experiencias en la movilidad académica, la formación doctoral del docente / Bernal Álava AF, Borroto Leal OE, Campozano Pluas, Vanessa Daniela -- La gestión de la internacionalización desde la perspectiva de la formación tecnológica: la experiencia del Instituto Superior Tecnológico Bolivariano de Tecnología ITB / Luis Alberto Alzate Peralta, Odette Martínez Pérez Elena Tolozano Benites -- 6.Las TIC y las Redes Sociales en la formación de los estudiantes / Las Redes sociales como gestoras de conocimiento formal en los participantes / Esteban de Jesús Gutiérrez Ortiz, Andrés Ernesto Manrique de la Cruz, Sheyla Monsait Valero Estrada, Carlos Jesús Rodríguez Saucedo -- Las NTIC como plataformas de nuevas habilidades digitales y cocreadoras de ecosistemas virtuales educomunicativos / Martín Hernández Oseguera, Oscar Ricardo Castillo BribiescaFundación Universitaria Los Libertadore